Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* WHITE ROBERT JOHN	2. Issuer Name and Ticker or Trading Symbol Medtronic plc [ MDT ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP & President MITG
(Last) (First) (Middle) MEDTRONIC PLC, 710 MEDTRONIC PKWY MS LC300	3. Date of Earliest Transaction (MM/DD/YYYY) 11/1/2019
(Street) MINNEAPOLIS, MN 55432 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	11/1/2019		M⁽¹⁾		9643	A	$29.52	61711 ⁽²⁾	D
Ordinary Shares	11/1/2019		S⁽¹⁾		3762	D	$109.659 ⁽³⁾	57949	D
Ordinary Shares	11/1/2019		M⁽¹⁾		37209	A	$36.58	95158	D
Ordinary Shares	11/1/2019		S⁽¹⁾		28428	D	$109.108 ⁽⁴⁾	66730	D
Ordinary Shares	11/1/2019		S⁽¹⁾		14662	D	$109.667 ⁽⁵⁾	52068	D
Ordinary Shares	11/1/2019		M⁽¹⁾		5313	A	$47.00	57381	D
Ordinary Shares	11/1/2019		S⁽¹⁾		3349	D	$109.113 ⁽⁶⁾	54032	D
Ordinary Shares	11/1/2019		S⁽¹⁾		1964	D	$109.663 ⁽⁷⁾	52068	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$29.52	11/1/2019		M ⁽¹⁾			9643	12/1/2012	11/30/2021	Ordinary Shares	9643	$0	0	D
Stock Option (Right to Buy)	$36.58	11/1/2019		M ⁽¹⁾			37209	12/3/2013	12/2/2022	Ordinary Shares	37209	$0	0	D
Stock Option (Right to Buy)	$47.00	11/1/2019		M ⁽¹⁾			5313	12/2/2014	12/1/2023	Ordinary Shares	5313	$0	25442	D

Explanation of Responses:
(1)	The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
(2)	This balance increased by 151 shares due to exempt transactions such as dividend reinvestment.
(3)	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.46 to $109.98, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(4)	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.44 to $109.44, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(5)	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.45 to $110.18, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(6)	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.46 to $109.43, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
(7)	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.46 to $110.01, inclusive. The reporting person undertakes to provide to Medtronic plc, any security holder of Medtronic plc or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
WHITE ROBERT JOHN MEDTRONIC PLC 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS, MN 55432			EVP & President MITG

Signatures
/s/ Perry F. Sekus, attorney-in-fact		11/4/2019
^**Signature of Reporting Person		Date

Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024

Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024

Medtronic Plc News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.